How to buy Eli Lilly and Company (LLY) shares in Australia
Learn how to easily invest in Eli Lilly and Company shares.
Eli Lilly and Company (LLY) is a leading drug manufacturers - general business with stocks listed in the US. It opened the day at US$592 after a previous close of US$591.53. During the day the price has varied from a low of USD590.78 to a high of USD595.38. The latest price was USD593.52 (25 minute delay). Eli Lilly and Company is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Eli Lilly and Company
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Eli Lilly and Company. Find the share by name or ticker symbol: LLY. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Eli Lilly and Company reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$591.53, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Eli Lilly and Company, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Eli Lilly and Company. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
What's in this guide?
- Eli Lilly and Company key stats
- Compare share trading platforms
- Is Eli Lilly and Company stock a buy or sell?
- Eli Lilly and Company performance over time
- Is Eli Lilly and Company suitable for ethical investing?
- Are Eli Lilly and Company shares over-valued?
- Eli Lilly and Company's financials
- How volatile are Eli Lilly and Company shares?
- Does Eli Lilly and Company pay a dividend?
- Have Eli Lilly and Company shares ever split?
- Other common questions
Eli Lilly and Company stock price (NYSE:LLY)Use our graph to track the performance of LLY stocks over time.
Have Eli Lilly and Company's shares ever split?
Eli Lilly and Company's shares were split on a 2:1 basis on 16 October 1997. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.
Eli Lilly and Company shares at a glance
|52-week range||US$307.1706 - US$628.8082|
|50-day moving average||US$578.3062|
|200-day moving average||US$466.5688|
|Dividend yield||US$4.37 (0.76%)|
|Earnings per share (TTM)||US$5.5|
Eli Lilly and Company price performance over time
|1 week (2023-11-21)||0.16%|
|1 month (2023-10-27)||5.94%|
|3 months (2023-08-28)||7.15%|
|6 months (2023-05-26)||39.39%|
|1 year (2022-11-28)||62.27%|
|2 years (2021-11-26)||127.95%|
|3 years (2020-11-27)||302.55%|
|5 years (2018-11-28)||413.74%|
Compare trading platforms to buy Eli Lilly and Company shares
Is it a good time to buy Eli Lilly and Company stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Eli Lilly and Company under- or over-valued?
Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Eli Lilly and Company's P/E ratio
Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 108x. In other words, Eli Lilly and Company shares trade at around 108x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Eli Lilly and Company's PEG ratio
Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1814. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Eli Lilly and Company's EBITDA
Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$11.3 billion (£8.9 billion).
The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure a its profitability.
Eli Lilly and Company share price volatility
Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as US$307.1706 up to US$628.8082. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.329. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).
Eli Lilly and Company financials
|Revenue TTM||US$32.1 billion|
|Operating margin TTM||37.28%|
|Gross profit TTM||US$21.9 billion|
|Return on assets TTM||11.63%|
|Return on equity TTM||46.46%|
|Market capitalisation||US$561.5 billion|
TTM: trailing 12 months
Eli Lilly and Company share dividends
Dividend payout ratio: 76.35% of net profits
Recently Eli Lilly and Company has paid out, on average, around 76.35% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.76% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 0.76% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $4.37 per share.
Eli Lilly and Company's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Eli Lilly and Company's most recent dividend payout was on 8 December 2023. The latest dividend was paid out to all shareholders who bought their shares by 14 November 2023 (the "ex-dividend date").
Eli Lilly and Company's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Eli Lilly and Company's total ESG risk score
Total ESG risk: 32.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 01/01/2019) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Eli Lilly and Company's environmental score
Environmental score: 0.63/100
Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Eli Lilly and Company's social score
Social score: 16.68/100
Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Eli Lilly and Company's governance score
Governance score: 13.31/100
Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Eli Lilly and Company's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||32.36|
|Total ESG percentile||70.22|
|Environmental score percentile||1|
|Social score percentile||1|
|Governance score percentile||1|
|Level of controversy||3|
Eli Lilly and Company overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Stocks similar to Eli Lilly and Company
Eli Lilly and Company in the news
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
Morning Brew: PDD Surges on Q3 Beat, ZS and RNA in Focus
3 Large Drug Stocks That Have Outperformed Industry YTD
Frequently asked questions
More guides on Finder
How to buy OpenAI stock in Australia
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Best performing stocks on the ASX in 2023 (Updated weekly)
Looking for the best performing stocks in Australia? We update this list weekly.
Cryptocurrency ETFs explained: A simple guide for investors (2023)
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
How to buy Gol Linhas Aereas Inteligentes SA ADR (GOL) shares in Australia
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
How to buy Microsoft (MSFT) shares in Australia
Steps to owning and managing Microsoft shares from in Australia.
A beginner’s guide to Lego investing
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
The cheapest stock brokers in Australia (Nov 2023)
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
What is the money market?
Learn about the money market and everyday consumer money market products.
Is investing in crowdfunding a safe investment?
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
The best trading platforms in Australia for 2023
Follow these tips to find the best share trading platform for you.
Ask an Expert